| Title |
Next generation of biologics for the treatment of Crohn’s disease: an evidence-based review on ustekinumab
|
|---|---|
| Published in |
Clinical and Experimental Gastroenterology, November 2017
|
| DOI | 10.2147/ceg.s110546 |
| Pubmed ID | |
| Authors |
Aranzazu Jauregui-Amezaga, Michael Somers, Heiko De Schepper, Elisabeth Macken |
| Abstract |
The limited efficacy of the currently available medical therapies in a proportion of patients with Crohn's disease has led to the research and development of molecules that can block new inflammatory pathways. Ustekinumab is a fully human IgG1 monoclonal antibody which targets the common p40 subunit of the cytokines interleukin-12 as well as interleukin-23. Consequently, the Th1 and Th17 inflammatory responses are inhibited. Ustekinumab has been recently approved for its use in patients with Crohn's disease. Its efficacy and safety was initially proved in patients with psoriasis and psoriatic arthritis. More recently, three Phase III trials have confirmed its efficacy in patients with Crohn's disease refractory to anti-tumor necrosis factor therapy. This biologic agent appears safe, with no increased risk of infectious or malignant complications, and a low immunogenic profile. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 81 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 81 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 14 | 17% |
| Researcher | 14 | 17% |
| Student > Ph. D. Student | 10 | 12% |
| Other | 6 | 7% |
| Student > Doctoral Student | 5 | 6% |
| Other | 7 | 9% |
| Unknown | 25 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 34 | 42% |
| Agricultural and Biological Sciences | 6 | 7% |
| Biochemistry, Genetics and Molecular Biology | 5 | 6% |
| Computer Science | 3 | 4% |
| Immunology and Microbiology | 2 | 2% |
| Other | 6 | 7% |
| Unknown | 25 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 September 2022.
All research outputs
#3,173,175
of 25,584,565 outputs
Outputs from Clinical and Experimental Gastroenterology
#49
of 311 outputs
Outputs of similar age
#58,007
of 341,375 outputs
Outputs of similar age from Clinical and Experimental Gastroenterology
#2
of 4 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 311 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 10.0. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 341,375 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.